Ascendis Pharma A/S 2023 SR
The report highlights Ascendis Pharma's 2023 sustainability performance, focusing on its TransCon technology platform and commitment to patients, science, and passion. Key achievements include launching the Compassionate Use Program for TransCon PTH in Germany and initiating the collection of Scope 1 and 2 greenhouse gas emissions data. The company also joined the Pharmaceutical Supply Chain Initiative (PSCI) to enhance supply chain sustainability and updated its global recruitment process to prioritize cultural fit. Furthermore, Ascendis Pharma achieved equal gender representation across all management levels and the Board of Directors.
Company: Ascendis Pharma A/S
Sector: Manufacturing
Country: Denmark
Year: 2023
Type: SR
Pages: 52
Back to company
Ascendis Pharma A/S
Sustainability And P|ESG Report
The report highlights Ascendis Pharma's 2023 sustainability performance, focusing on its TransCon technology platform and commitment to patients, science, and passion. Key achievements include launching the Compassionate Use Program for TransCon PTH in Germany and initiating the collection of Scope 1 and 2 greenhouse gas emissions data. The company also joined the Pharmaceutical Supply Chain Initiative (PSCI) to enhance supply chain sustainability and updated its global recruitment process to prioritize cultural fit. Furthermore, Ascendis Pharma achieved equal gender representation across all management levels and the Board of Directors.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees